From WisPolitics.com/WisBusiness.com …
— Madison-based Nimble Therapeutics is being acquired for $200 million by AbbVie, the Chicago-area pharmaceutical company announced.
In a recent release, AbbVie said it’s buying Nimble and its “lead asset,” a drug in the preclinical stage of development for the treatment of psoriasis and inflammatory bowel disease. It focuses on a therapeutic target that contributes to these conditions through increased inflammation and an “amplified” immune response.
The acquisition covers Nimble’s other drug candidates with “potential across several autoimmune diseases,” the announcement shows, as well as its drug discovery and optimization platform.
Jigar Patel, founder and CEO of Nimble Therapeutics, says AbbVie’s expertise in commercializing medicines around the world will help Nimble’s oral therapies reach more people.
“We are pleased that AbbVie has recognized the tremendous potential of our proprietary platform and emerging immunology pipeline,” Patel said in the release, which also notes Nimble has been backed by founding investors Roche Ventures and Telegraph Hill Partners.
Jonathan Sedgwick, senior vice president and global head of discovery research for AbbVie, touts the opportunity to “help address the significant unmet medical need” for patients with autoimmune diseases.
“The addition of Nimble’s pipeline to AbbVie’s existing pipeline, combined with our deep clinical and translational expertise in immunology, represents an important growth opportunity,” he said in a statement.
See more in the release below.
Top Stories
– How are states spending their opioid settlement cash? Look yours up in this database
– Weight-loss drugs draw Americans back to the doctor
– Trump says there are ‘problems’ with vaccines, rejects mandates
– Polio vax petition could preview more challenges
– Helicopters Rescued Patients in ‘Apocalyptic’ Flood. Other Hospitals Are at Risk, Too.
– Sanders defends Warren comments on ‘outrageous’ UnitedHealthcare CEO killing
Press Releases
– AbbVie: To acquire Nimble Therapeutics, further strengthening immunology pipeline
